FDA approves novel infusion therapy for Parkinson’s disease

The U.S. Food and Drug Administration has approved a novel therapy to treat patients with advanced Parkinson’s disease.

Foscarbidopa and foslevodopa is a subcutaneous 24-hour continuous infusion therapy designed to manage motor fluctuations, according to an AbbVie press release reported in PR Newswire. The treatment was approved following positive results in a phase III study involving 130 patients with advanced Parkinson’s disease.

Researchers found that compared with oral immediate-release carbidopa/levodopa, foscarbidopa and foslevodopa demonstrated superior improvement in the periods of time in which the patients experienced optimal motor symptom control without dyskinesia.

The most common treatment-related adverse events included sudden onset of sleep, hallucinations, unusual urges, infusion-site reactions and infections, worsening glaucoma, cardiovascular events and dyskinesia.

Clinicians were advised to discuss the potential benefits and risks of continuous levodopa administration with their patients.

Read more: PR Newswire

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.